The Technical Analyst
Coherus BioSciences Inc [CHRS]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Coherus BioSciences Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
0.46% $2.19
America/New_York / 23 apr 2024 @ 11:02
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 248.56 mill |
| EPS: | -2.53 |
| P/E: | -0.870 |
| Earnings Date: | May 06, 2024 |
| SharesOutstanding: | 113.50 mill |
| Avg Daily Volume: | 2.84 mill |
| RATING 2024-04-22 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Sell | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.870 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.15x |
| Company: PE -0.870 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 2.02 - 2.39 ( +/- 8.34%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-02-20 | Erbez Georgia | Buy | 54 000 | Stock Option (Right to Buy) |
| 2024-02-20 | Erbez Georgia | Buy | 0 | |
| 2024-02-09 | Wahlstrom Mats | Buy | 99 988 | Common Stock |
| 2024-02-09 | Wahlstrom Mats | Sell | 99 988 | Common Stock |
| 2024-02-01 | Wahlstrom Mats | Buy | 44 991 | Common Stock |
| INSIDER POWER |
|---|
| 42.75 |
| Last 94 transactions |
| Buy: 4 570 164 | Sell: 1 886 237 |
Forecast:
12:41 - $2.20
Live Trading Signals (every 1 min)
Forecast
1: 11:11 - $2.19
Forecast 2: 12:01 - $2.20
Forecast 3: 12:41 - $2.20
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $2.19 (0.46% ) |
| Volume | 0.201 mill |
| Avg. Vol. | 2.84 mill |
| % of Avg. Vol | 7.09 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CHRS
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | buy | $2.36 | N/A | Active |
|---|
CHRS
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
Latest Press Releases
2024-04-08 08:30:00 - Press Release
Coherus Presents Preclinical Data For Chs-1000, A Novel Anti-ilt4 Antibody, At The 2024 Aacr Annual Meeting
– in preclinical studies, chs-1000 shows a high affinity for human ilt4, reverses ilt4-mediated immunosuppressive functions, leading to activation of immune cells and increased cytokine secretion – – mechanism may enhance antitumor responses with immunotherapy – – first novel immuno-oncology product candidate discovered and developed by coherus – – the chs-1000 ind submission is planned for q2 2024 –
2024-03-13 16:01:00 - Press Release
Coherus Biosciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
– net revenue of $91.5 million in the fourth quarter and $257.2 million in fy 2023 – – udenyca® net sales of $36.2 million in the fourth quarter and $127.1 million in fy 2023 – – cimerli® net sales of $52.4 million in the fourth quarter and $125.4 million in fy 2023 – – loqtorzi™ and udenyca onbody™ successfully launched in q1 2024 – – reduction of work force of 30% for 2024 initiated on march 7, 2024 – – conference call today at 5:00 p.m. eastern time – redwood city, calif.
2024-03-05 16:01:00 - Press Release
Coherus To Report Fourth Quarter And Full Year 2023 Financial Results On March 13, 2024
Redwood city, calif., march 05, 2024 (globe newswire) -- coherus biosciences, inc. (“coherus,” nasdaq: chrs) today announced that its fourth quarter and full year 2023 financial results will be released after market close on wednesday, march 13, 2024. starting at 5:00 pm et on march 13, 2024, coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update.
2024-03-04 01:00:00 - Press Release
Coherus Completes Divestiture Of Ophthalmology Franchise
– upfront cash payment of $170 million strengthens capital structure – – transaction solidifies coherus' strategic focus in oncology – redwood city, calif., march 04, 2024 (globe newswire) -- coherus biosciences, inc. (nasdaq: chrs) today announced the completion of the previously announced divestiture of its cimerli® (ranibizumab-eqrn) ophthalmology franchise through the sale of its subsidiary, coherus ophthalmology llc, to sandoz, inc. for upfront all-cash consideration of $170 million.
2024-02-23 17:33:00 - Press Release
Coherus Biosciences Announces New Employment Inducement Grants
Redwood city, calif., feb. 23, 2024 (globe newswire) -- coherus biosciences, inc. (“coherus” or the “company”, nasdaq: chrs), today announced that effective february 20, 2024, the compensation committee of the company's board of directors granted options to purchase an aggregate of 170,000 shares of the common stock of the company to three newly hired employees with a per share exercise price of $2.59, the closing trading price on the grant date. one executive vice president level executive was granted an option to purchase 150,000 shares; and two additional non-officer employees were granted options to purchase an aggregate of 20,000 shares.
Latest News
2024-03-20 20:14:44 - Seeking Alpha
Coherus Biosciences: Dumping One Drug But Showing Promise With Another
CHRS has sold Cimerli, a Lucentis biosimilar, to SDZNY. CHRS anti-IL-27 antibody, casdozokitug, shows promising results as part of a triple therapy in hepatocellular carcinoma, with an overall response rate of 38%. Numbers on market share point to a strong Q1'24 for Udenyca, which could increase the market's confidence that CHRS can offset lost revenues from the Cimerli sale.
2024-03-14 18:28:43 - The Motley Fool
Why Coherus Biosciences Stock Tumbled on Thursday
The biotech unveiled its latest set of quarterly and annual results. Its revenue for the former period rose sharply, but missed analyst expectations -- as did its bottom-line result.
2024-03-13 20:56:10 - Seeking Alpha
Coherus BioSciences, Inc. (CHRS) Q4 2023 Earnings Call Transcript
2024-02-06 17:16:03 - The Motley Fool
Why Coherus BioSciences Stock Jumped Today
Following the closing of its recently announced divestiture of its noncore ophthalmology business, Coherus will prepay a huge chunk of its term loan with Pharmakon. The move will reduce interest expenses by 70%, allowing Coherus to hone its focus on its oncology products.
2024-01-23 11:37:14 - The Motley Fool
Why Coherus BioSciences Stock Is Sinking Today
Coherus BioSciences stock initially jumped after the announcement of a deal to sell Cimerli to Sandoz. However, shares are now sinking with investors reminded of the financial challenges that Coherus faces.
2024-01-22 15:41:00 - The Motley Fool
Why Coherus Biosciences Popped Today
Coherus announced a $170 million deal to divest Cimerli to Sandoz Group. The company is paying down debt and refocusing on its core oncology business.
2024-01-22 08:38:00 - InvestorPlace
Why Is Coherus BioSciences (CHRS) Stock Up 17% Today?
Coherus BioSciences (NASDAQ: CHRS ) stock is taking off on Monday after the biopharmaceutical company announced a $170 million divestment. Coherus BioSciences is selling its CIMERLI ophthalmology franchise to Sandoz (OTCMKTS:SDZNY) for an upfront payment of $170 million.
2024-01-03 09:00:00 - GlobeNewsWire
Coherus BioSciences Management to Present at the 42nd Annual J.P. Morgan Healthcare Conference
REDWOOD CITY, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” Nasdaq: CHRS), today announced that senior management will present at the upcoming 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 9:45 a.m. Pacific Time. The presentation and Q&A session will be accessible via Webcast through a link posted on the Investor Events Calendar section of the Coherus website: https://investors.coherus.com/upcoming-events. This webcast will be available for replay until February 9, 2024.
2023-12-28 15:45:29 - The Motley Fool
Why Coherus BioSciences Stock Jumped Today
After months of delays following an FDA review of its Udenyca OnBody biologics license application, Coherus has finally received FDA approval for the product. Coherus is planning commercial availability of Udenyca OnBody for the first quarter of 2024.
2023-12-28 12:47:27 - Zacks Investment Research
Coherus (CHRS) Stock Rallies on FDA Nod for Udenyca Onbody
The FDA approves Coherus' (CHRS) Udenyca Onbody, an on-body injector presentation of Udenyca (pegfilgrastim-cbqv). Shares of the company rise on the news.